8-K: Sight Sciences Reports Mixed Q2 Results, Narrows Full Year Guidance Amid Dry Eye Strategy Shift

Sight Sciences reported a decrease in year-over-year revenue for the second quarter of 2024, while narrowing its full-year financial guidance due to a strategic shift in its Dry Eye business.

Summary

• Sight Sciences announced its second quarter 2024 financial results, showing a total revenue of $21.4 million, which is an 11% increase compared to the previous quarter but a 9% decrease compared to the same period last year.
• The company's gross margin remained stable at 86% year-over-year.
• Cash usage was reduced to $9.1 million, a 29% decrease compared to the $12.8 million used in the second quarter of 2023.
• Surgical Glaucoma saw a 5% increase in both ordering account utilization and active accounts compared to the first quarter of 2024.
• The company plans to increase the list price of TearCare SmartLids to $1,200 per set, effective October 1, 2024.
• The Centers for Medicare and Medicaid Services (CMS) has proposed increased Medicare facility payment rates for canaloplasty procedures using CPT code 66174, effective January 1, 2025.
• The company has narrowed its full-year 2024 revenue guidance to approximately $81.0 million to $83.0 million, representing growth of approximately 0% to 2% compared to 2023.
• The company expects dry eye revenue for full year 2024 to be less than $3.0 million.
• Adjusted operating expenses for full year 2024 are expected to be approximately $107.0 million to $109.0 million, a decrease of approximately 1% to 3% compared to 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are some positive aspects like reduced cash usage and growth in the Surgical Glaucoma segment, the overall revenue decline, narrowed guidance, and expected decrease in dry eye revenue weigh negatively on the outlook.

Positives

• The company achieved an 11% increase in total revenue compared to the previous quarter.
• Cash usage decreased by 29% year-over-year, indicating improved operational efficiency.
• Surgical Glaucoma segment showed positive growth in account utilization and active accounts.
• The proposed CMS rule could significantly increase Medicare payments for canaloplasty procedures.
• The company is focusing on market access for its Dry Eye business, which could lead to future growth.

Negatives

• Total revenue decreased by 9% compared to the same quarter last year.
• Dry Eye revenue decreased by 46% compared to the same period last year.
• The company expects a decrease in Dry Eye revenue in the second half of 2024 due to a price increase, which will negatively impact cash-pay procedure volumes.
• The company has narrowed its full-year revenue guidance, indicating slower growth than previously anticipated.

Risks

• Changes in the reimbursement environment, including coverage decisions and reimbursement rates, could impact revenue.
• The outcome of clinical trials may affect the adoption of the company's products.
• Legal proceedings or regulatory matters could pose risks to the company.
• Changes in economic conditions, including discretionary spending and inflationary pressures, could affect sales.
• Supply chain disruptions, constraints, and related expenses could impact the company's ability to produce and sell its products.
• The company's forward-looking statements are subject to significant risks and uncertainties that limit its ability to accurately forecast results.

Future Outlook

The company expects double-digit surgical glaucoma revenue growth in the second half of 2024, but anticipates a decrease in dry eye revenue due to a price increase. They expect a return to growth in the dry eye segment in 2025 with market access wins. Full year revenue is expected to be between $81.0 million and $83.0 million, and adjusted operating expenses are expected to be between $107.0 million and $109.0 million.

Management Comments

• Paul Badawi, co-founder and CEO, stated that the company continued to establish commercial momentum in the Surgical Glaucoma segment.
• Mr. Badawi also mentioned that the company is advancing its Dry Eye business with further clinical and market access progress.
• Management intends to ensure the value of the TearCare technology is appropriately distributed across stakeholders by pioneering market access for interventional dry eye procedures.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the medical device industry, particularly in the eyecare sector. The company's focus on interventional treatments for glaucoma and dry eye aligns with a broader trend towards minimally invasive procedures and addressing the underlying causes of diseases rather than just managing symptoms. The proposed increase in Medicare payments for canaloplasty procedures could be a positive development for the company and the broader MIGS market.

Comparison to Industry Standards

• Sight Sciences' Surgical Glaucoma revenue decreased by 5% year-over-year, which is a mixed result compared to other companies in the MIGS space, some of which have shown growth.
• The company's gross margin of 86% is strong and indicates efficient cost management, which is comparable to other medical device companies with established products.
• The 29% reduction in cash usage is a positive sign of improved operational discipline, which is a key metric for investors in the medical device sector.
• The proposed increase in Medicare payments for canaloplasty procedures could give Sight Sciences a competitive advantage over companies that do not have a similar product offering.
• The company's dry eye revenue decline of 46% year-over-year is a significant concern, especially when compared to other companies in the dry eye market that have shown growth. This highlights the challenges of commercializing new dry eye technologies and the importance of market access.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and narrowed guidance.
• Employees may be affected by the company's strategic shift in the Dry Eye business.
• Customers may be impacted by the price increase for TearCare SmartLids.
• Payors may be impacted by the proposed increase in Medicare payments for canaloplasty procedures.

Next Steps

• The company will implement a price increase for TearCare SmartLids on October 1, 2024.
• The company will continue to pursue market access for its Dry Eye business.
• The company will continue to develop its pipeline of products.
• The company will monitor the finalization of the proposed CMS rule regarding increased Medicare payments for canaloplasty procedures.

Key Dates

Keywords

glaucoma, dry eye, OMNI Surgical System, TearCare, revenue, MIGS, reimbursement, canaloplasty, Medicare, SAHARA RCT